申请人:COCRYSTAL PHARMA, INC.
公开号:US10464914B2
公开(公告)日:2019-11-05
The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
本发明除其他外提供了通式I所代表的化合物:(I)及其药学上可接受的盐,其中L和A(以及进一步的取代基)如本文类和亚类所定义,以及包含此类化合物的组合物(例如药物组合物),这些化合物可用作丙型肝炎病毒聚合酶的抑制剂,因此可用作例如治疗HCV感染的药物。